Requirements and expectations of high‐quality biomarkers for atopic dermatitis and psoriasis in 2021—a two‐round Delphi survey among international experts

Journal of the European Academy of Dermatology and Venereology - Tập 36 Số 9 - Trang 1467-1476 - 2022
Stefanie Ziehfreund1, Linda Tizek1, Nora Hangel2, Marie-Christine Fritzsche2, S. Weidinger3, Catherine Smith4, Paul Bryce5, Dario Greco6,7, Ellen H. van den Bogaard8, Carsten Flohr9, Joe Rastrick10, Stefanie Eyerich11, Alena Buyx2, Curdin Conrad12, Kilian Eyerich1,13,14, Alexander Zink1,14
1Department of Dermatology and Allergy, Technical University of Munich, School of Medicine, Munich, Germany
2Institute for History and Ethics of Medicine, Technical University of Munich, Munich, Germany
3Department of Dermatology and Allergy, University Hospital Schleswig-Holstein, Kiel, Germany
4St John's Institute of Dermatology, Kings College London and Guys and St Thomas' NHS Foundation Trust, Guy's Hospital, London, UK
5Type 2 Inflammation & Fibrosis Cluster Immunology & Inflammation Therapeutic Area, Sanofi US Cambridge Massachusetts USA
6Faculty of Medicine and Health Technology, BioMediTech Institute, Tampere University, Tampere, Finland
7Institute of Biotechnology, Helsinki Institute for Life Science (HiLife), University of Helsinki, Helsinki, Finland
8Department of Dermatology, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, Nijmegen, the Netherlands
9Unit for Population-Based Dermatology Research, St John's Institute of Dermatology, School of Basic and Medical Biosciences, King's College London, London, UK
10Immunology Research, New Medicines UCB Pharma, Slough, UK
11Center of Allergy and Environment (ZAUM), Technical University and Helmholtz Center Munich, Munich, Germany
12Department of Dermatology, Lausanne University Hospital CHUV, Lausanne, Switzerland
13Department of Dermatology and Venereology, Medical Center, University of Freiburg, Freiburg, Germany
14Division of Dermatology and Venerology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden

Tóm tắt

AbstractBackgroundChronic inflammatory skin diseases such as atopic dermatitis (AD) and psoriasis (PSO) present major challenges in health care. Thus, biomarkers to identify disease trajectories and response to treatments to improve the lives of affected individuals warrant great research consideration. The requirements that these biomarkers must fulfil for use as practical clinical tools have not yet been adequately investigated.AimTo identify the core elements of high‐quality AD and PSO biomarkers to prepare recommendations for current biomarker research.MethodA cross‐sectional two‐round Delphi survey was conducted from August to October 2019 and October to November 2020. All participants were members of the BIOMAP project, an EU‐funded consortium of clinicians, researchers, patient organizations and pharmaceutical industry partners. The first round consisted of three open‐ended questions. Responses were qualitatively analysed, and 26 closed statements were developed. For the second round, ‘agreement’ was assumed when the responses of ≥70% of the participants were ≥5 points on a 7‐point Likert scale for each statement. Priority classification was based on mean scores (<20th percentile = low, 20th to 60th percentile = medium, >60th percentile = high).ResultsTwenty‐one and twenty‐six individuals participated in rounds one and two, respectively. From 26 statements that were included in round 2, 18 achieved agreement (8 concerning the performance, 8 for the purpose and 2 on current obstacles). Seven statements were classified as high priority, e.g. those concerning reliability, clinical validity, a high positive predictive value, prediction of the therapeutic response and disease progression. Another seven statements were assigned medium priority, e.g. those about analytical validity, prediction of comorbidities and therapeutic algorithm. Low priority included four statements, like those concerning cost effectiveness and prediction of disease flares.ConclusionThe core requirements that experts agreed on being essential for high‐quality AD and PSO biomarkers require rapid validation. Biomarkers can therefore be assessed based on these prioritized requirements.

Từ khóa


Tài liệu tham khảo

10.1111/bjd.19580

10.1111/bjd.19169

10.1016/j.clindermatol.2018.05.007

10.1016/j.jaad.2018.05.1241

10.1111/all.13320

10.2340/00015555-3510

10.1111/jdv.13854

10.1371/journal.pone.0132454

10.1111/jdv.14673

10.1038/s41572-018-0001-z

10.1038/nrdp.2016.82

10.1016/j.jaci.2020.02.017

10.1111/ijd.14864

10.1111/jdv.17110

10.1111/jdv.15634

10.2340/00015555-3102

World Health Organication & International Programme on chemical safety, 2001, Biomarkers in Risk Assessment: Validity and Validation

10.1016/j.jaci.2021.01.013

10.1186/s13075-021-02545-4

10.1111/all.14557

Biomap.About BIOMAP. Towards Personalised Medicine for Inflamatory Skin Diseases. URL:https://biomap‐imi.eu/about(last accessed 15 November2021)

10.1002/9783527622153.ch33

10.1002/gps.5292

10.1177/0962280207082719

10.1016/j.molonc.2012.01.010

10.1016/S0895-4356(03)00211-7

10.1046/j.1365-2648.2000.t01-1-01567.x

FDA‐NIH Biomarker Working Group, 2016, BEST (biomarkers, EndpointS, and other tools) Recource [internet]

10.1177/030802269806100403

10.1016/j.jaci.2019.11.047

PsoBest.Das Deutsche Psoriasis‐Register. URL:https://www.psobest.de/das‐register/(last accessed 15 November 2021).

TREATgermany.Deutsches Neurodermitis‐Register. URL:http://www.treatgermany.org(last accessed 15 November 2021).

MAPS.Munich Atopy Prediction Study. URL:https://www.mri.tum.de/dermatologie(last accessed 15 November 2021).

The BIOMAP Consortium.BIOMAP glossary. URL:https://zenodo.org/record/4746584#.YPanEy1Q1MM(last accessed 15 November 2021).

10.1111/bjd.20587

Aitken M, 2020, Optimizing oncology care through biomarker adoption: BARRIERS AND SOLUTIONS

Loughlin KG, 1979, Using Delphi to achieve congruent objectives and activities in a pediatrics department, J Med Educ, 54, 101

10.1111/j.1365-2648.2006.03716.x

10.1111/j.1365-2648.1994.tb01066.x

10.1016/S0020-7489(00)00044-4

10.1016/0040-1625(79)90011-8

Thông tin
Thông tin xuất bản

Journal of the European Academy of Dermatology and Venereology

Tập 36 Số 9

1467-1476

Thông tin tác giả